BioDelivery Sciences International, Inc. (NASDAQ:BDSI) posted its quarterly earnings results on Wednesday. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.04, Briefing.com reports. The company had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.45 million. BioDelivery Sciences International had a negative return on equity of 1.45% and a negative net margin of 0.19%. The company’s revenue for the quarter was up 74.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.31) earnings per share.

Shares of BioDelivery Sciences International (BDSI) traded down 5.556% during mid-day trading on Thursday, reaching $2.975. 691,573 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $3.04 and its 200-day moving average price is $2.25. The stock’s market cap is $164.59 million. BioDelivery Sciences International has a 12-month low of $1.50 and a 12-month high of $3.60.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/biodelivery-sciences-international-inc-nasdaqbdsi-announces-earnings-results/1468917.html.

Institutional investors have recently bought and sold shares of the company. Hikari Power Ltd increased its position in BioDelivery Sciences International by 127.2% in the second quarter. Hikari Power Ltd now owns 601,285 shares of the specialty pharmaceutical company’s stock worth $1,684,000 after buying an additional 336,675 shares during the last quarter. Cutter & CO Brokerage Inc. boosted its stake in BioDelivery Sciences International by 2.4% in the second quarter. Cutter & CO Brokerage Inc. now owns 43,430 shares of the specialty pharmaceutical company’s stock worth $122,000 after buying an additional 1,000 shares during the last quarter. Valley National Advisers Inc. boosted its stake in BioDelivery Sciences International by 59.0% in the second quarter. Valley National Advisers Inc. now owns 37,715 shares of the specialty pharmaceutical company’s stock worth $106,000 after buying an additional 14,000 shares during the last quarter. Blair William & Co. IL boosted its stake in BioDelivery Sciences International by 112.2% in the second quarter. Blair William & Co. IL now owns 1,471,122 shares of the specialty pharmaceutical company’s stock worth $4,119,000 after buying an additional 777,941 shares during the last quarter. Finally, Sterling Investment Management Inc. purchased a new stake in BioDelivery Sciences International during the second quarter worth approximately $140,000. 40.40% of the stock is currently owned by institutional investors.

BDSI has been the subject of a number of analyst reports. Roth Capital set a $5.00 price objective on shares of BioDelivery Sciences International and gave the company a “buy” rating in a report on Tuesday, May 16th. Janney Montgomery Scott lifted their price objective on shares of BioDelivery Sciences International from $3.00 to $4.00 and gave the company a “fair value” rating in a report on Monday, July 24th. Cantor Fitzgerald upgraded shares of BioDelivery Sciences International from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $3.00 to $4.00 in a report on Tuesday, May 16th. HC Wainwright assumed coverage on shares of BioDelivery Sciences International in a report on Friday, May 26th. They set a “buy” rating and a $4.00 price target on the stock. Finally, Zacks Investment Research cut shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Monday, July 17th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $4.14.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Earnings History for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.